SVRA

Savara (SVRA)

About Savara (SVRA)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Details

Daily high

$6.17

Daily low

$5.98

Price at open

$6.07

52 Week High

$7.00

52 Week Low

$1.89

Market cap

1.2B

Dividend yield

0.00%

Volume

9.7M

Avg. volume

4.6M

P/E ratio

-11.31

Savara News